Won the “Social Public Welfare Award” of China Cancer Foundation Experts think highly of the cervical cancer screening solution of Sansure Biotech
In order to fully implement the “Healthy China 2030” strategy and special actions, on April 24, the “19th Annual Meeting of National Cervical Cancer Consortium and Symposium of Cervical Cancer Prevention in China” hosted by Cancer Foundation of China, National Cancer Institute/Cancer Hospital of Chinese Academy of Medical Sciences Hospital was grandly held in Beijing.
More than 400 experts in the field of cervical cancer prevention and control from all over the country gathered to focus on the latest research progress in the field of cervical cancer prevention and control at home and abroad, with the purpose of helping the development of the prevention and control of national cervical cancer.
Charity Awards Ceremony on International Working Women’s Day
Sansure Biotech won the Social Welfare Award
“There are a total of 101 cities and 205 provincial and municipal hospitals organized screening public welfare activities across the country.” Before the meeting, Charity Awards Ceremony on International Working Women’s Day first gave some favorable comments on the Charity Awards Ceremony in 2021. At the awards ceremony, Sansure Biotech was awarded the “Social Public Welfare Award” issued by the Cancer Foundation of China. The self-developed rapid nucleic acid release technology HPV product and portable POCT (iPonatic) were well received at the conference.
In this year’s activities, companies such as Sansure Biotech and Kingmed Diagnostics donated materials worth 7.61 million yuan, and provided free cervical cancer screening for 22,027 low-income women. There were 240 cases detected with cervical lesions (CIN1: 147 cases, CIN2: 52 cases, CIN3: 41 cases) and 13 cases of cervix cancer. 13574 low-income women were provided with free breast cancer screening, and 298 popular science lectures were held, bringing love and warmth to the majority of women.
It is understood that the Cancer Foundation of China has launched the charity for the health and happiness of women for 16 consecutive years, and has conducted free cervical and breast cancer screenings for more than 100,000 low-income women.
Sansure Biotech Symposium
Experts think highly of the cervical cancer screening solution of Sansure Biotech
The Sansure Biotech Symposium was chaired by Professor Youlin Zhao, and Professor Fanghui Zhao from National Cancer Institute/Cancer Hospital of Chinese Academy of Medical Sciences Hospital delivered a special academic report on “Study on a Rapid Nucleic Acid Release Technology HPV Kit” to the delegates.
“Currently, the screening coverage rate in China is less than 40%, and the HPV vaccine coverage rate is even lower (less than 1%).” Professor Fanghui Zhao believed that the promotion and application of high-quality HPV testing products with high detection efficiency, high sensitivity and high accuracy should be increased, so as to achieve high efficiency and precision in the screening and follow-up process, and to save the time of patient follow-up review, providing a better follow-up management.
“In a number of study projects conducted under the guidance of our team, the HPV detection kit with high throughput and rapid nucleic acid release technology independently developed by Sansure Biotech have demonstrated excellent performance. With its portable POCT (iPonatic), it achieves breakthroughs in molecular diagnostic technology from hourly level (5-6h) to minute level (<30min).” Professor Fanghui Zhao said that more attention should be paid to the development of local technologies for cervical cancer screening; and should be develop in the direction of simplicity, speed, accuracy and typing. Innovative strategies such as self-sampling, POCT&HPV detection technology (preliminary screening + typing in one), Screen and Treat should be developed to improve the effectiveness of cervical cancer screening.
In the future, Sansure Biotech will actively respond to the implementation of the Healthy China 2030 strategy and WHO’s accelerated elimination of cervical cancer strategy. We are committed to making genetic technology benefit the public, continuing to accelerate the elimination of cervical cancer and contribute to the cause of women’s health.
